MarketCap
Facebook
X
Telegram
Globus Medical Operating Income | GMED
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Globus Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 480 M | 166 M | 133 M | 228 M | 172 M | 111 M | 172 M | 169 M | 162 M | 154 M | 172 M | 138 M | 102 M | 115 M | 97.4 M | 87.7 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 480 M | 87.7 M | 166 M |
Quarterly Operating Income Globus Medical
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 150 M | 137 M | 76.1 M | 97 M | 48.1 M | 49.6 M | 8 M | 404 K | 66.2 M | 56.4 M | - | 59.7 M | 67.8 M | 46.4 M | - | 53.3 M | 45.9 M | 54.5 M | - | 50 M | -25.6 M | 28.4 M | - | 42.1 M | 42.9 M | 37.1 M | - | 38.3 M | 42.1 M | 45.6 M | - | 35.8 M | 37.4 M | 40.3 M | - | 37.6 M | 37.9 M | 42.9 M | - | 40.7 M | 37 M | 38.5 M | - | 34.9 M | 31.6 M | 32.2 M | - | 29.5 M | 11.2 M | 29.2 M | - | 27.1 M | 30.6 M | 28.1 M | - | 26.5 M | 23.8 M | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 150 M | -25.6 M | 43.8 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M |  USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | - | - | $ 162 M |  France |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-26.1 M | - | - | $ 3.31 B | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
LENSAR
LNSR
|
-24.6 M | $ 5.6 | -2.78 % | $ 67 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
-71.1 M | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Outset Medical
OM
|
-66.7 M | $ 4.04 | -4.49 % | $ 61.5 K | USA |
 |
AxoGen
AXGN
|
-7.85 M | $ 39.49 | -0.6 % | $ 1.82 B | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Insulet Corporation
PODD
|
474 M | $ 163.26 | 3.08 % | $ 11.5 B | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Quanterix Corporation
QTRX
|
-126 M | $ 3.67 | -6.38 % | $ 156 M | USA |
 |
Bruker Corporation
BRKR
|
68.2 M | $ 60.45 | -2.74 % | $ 9.18 B | USA |
 |
Sintx Technologies
SINT
|
-10.7 M | $ 1.42 | -6.58 % | $ 3.94 M | USA |
 |
TELA Bio
TELA
|
-33.8 M | $ 0.69 | -2.81 % | $ 32.4 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Tactile Systems Technology
TCMD
|
29.3 M | $ 27.48 | 0.15 % | $ 629 M | USA |
 |
TransMedics Group
TMDX
|
109 M | $ 72.26 | 1.59 % | $ 2.46 B | USA |
 |
IRIDEX Corporation
IRIX
|
-2.57 M | $ 0.89 | -3.38 % | $ 15.1 M | USA |
 |
Tandem Diabetes Care
TNDM
|
8.29 M | $ 17.12 | 1.3 % | $ 1.16 B | USA |
 |
Second Sight Medical Products
EYES
|
-27.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
ClearPoint Neuro
CLPT
|
-24.2 M | $ 14.12 | -2.55 % | $ 400 M | USA |
 |
Viemed Healthcare
VMD
|
22.9 M | $ 11.77 | 0.86 % | $ 458 M | USA |
 |
Avanos Medical
AVNS
|
-61.6 M | $ 24.99 | 0.04 % | $ 1.16 B | USA |
 |
Beyond Air
XAIR
|
-29 M | $ 5.16 | -5.67 % | $ 42.8 B | USA |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
Xtant Medical Holdings
XTNT
|
7.28 M | $ 0.43 | -0.39 % | $ 60 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-14.7 M | $ 0.36 | -0.39 % | $ 22.4 M | USA |
 |
NanoVibronix
NAOV
|
-22.9 M | - | - | $ 1.08 M | USA |
 |
Natus Medical Incorporated
NTUS
|
23.8 M | - | 1.94 % | $ 1.05 B | USA |
 |
Nevro Corp.
NVRO
|
-126 M | - | - | $ 217 M | USA |
 |
Inogen
INGN
|
-30.2 M | $ 6.15 | -2.69 % | $ 164 M | USA |